Highlights
- •Somatic NTRK1 and NTRK3 fusions have high specificity for papillary thyroid cancer.
- •In pediatric PTC, NTRK fusions are associated with a high rate of regional and distant metastases.
- •Future studies needed to develop clinically relevant pediatric models of thyroid cancer.
Abstract
Pediatric and adult papillary thyroid cancer (PTC) share many similar oncogenic drivers,
but differ in the pathological features and outcomes of the disease. The most frequent
genetic alterations in adult PTCs are mutually exclusive point mutations in BRAF or the RAS family. In pediatric PTC, fusion oncogenes involving chromosomal translocations in
tyrosine kinase (TK) receptors, most commonly RET and NTRK, are the most common genetic alterations observed. This review of the literature
describes the current state of translational research in pediatric NTRK-driven thyroid
cancer and highlights opportunities to improve our understanding and current models
of pediatric PTC.
Keywords
Abbreviations:
PTC (Papillary thyroid cancer), NIS (Sodium-iodide symporter), RAI (Radioactive iodine)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Cancer GeneticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Kinase impact assessment in the landscape of fusion genes that retain kinase domains: a pan-cancer study.Brief Bioinform. 2018; 19 (PubMed PMID: 28013235; PMCID: PMC5952959): 450-460https://doi.org/10.1093/bib/bbw127
- RET gene fusions in malignancies of the thyroid and other tissues.Genes (Basel). 2020; 11 (PubMed PMID: 32326537; PMCID: PMC7230609)https://doi.org/10.3390/genes11040424
- Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.Ann Oncol. 2019; 30 (SupplPubMed PMID: 32223939): viii5-viii15https://doi.org/10.1093/annonc/mdz383
- NTRK fusions identified in pediatric tumors: the frequency, fusion partners, and clinical outcome.JCO Precis Oncol. 2021; 1 (PubMed PMID: 34036219; PMCID: PMC8140782 manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Elizabeth FoxOther Relationship: Helsinn TherapeuticsGerald B. WertheimEmployment: Johnson & Johnson Stock and Other Ownership Interests: Johnson & JohnsonVinodh PillaiConsulting or Advisory Role: Foundation medicine Travel, Accommodations, Expenses: Foundation MedicineJennifer E. PogorilerEmployment: Bristol-Myers Squibb Stock and Other Ownership Interests: Bristol-Myers SquibbStephen P. HungerStock and Other Ownership Interests: Amgen, Merck Honoraria: Amgen Consulting or Advisory Role: NovartisAndrew J. BauerHonoraria: Sandoz-Novartis Travel, Accommodations, Expenses: SandozMarilyn M. LiConsulting or Advisory Role: Roche No other potential conflicts of interest were reported)https://doi.org/10.1200/PO.20.00250
- Fusion-oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers.bioRxiv. 2021; (2021.07.23.453235)https://doi.org/10.1101/2021.07.23.453235
- The addition of microRNA expression testing increases the sensitivity and specificity to detect thyroid cancer in pediatric patients.Am Thyroid Assoc Annu Meet. 2019; (Chicago, IL)
- Molecular testing for oncogenic gene alterations in pediatric thyroid lesions.Thyroid. 2018; 28 (PubMed PMID: 29108474; PMCID: PMC5770125): 60-67https://doi.org/10.1089/thy.2017.0059
- American thyroid association guidelines task F. Management guidelines for children with thyroid nodules and differentiated thyroid cancer.Thyroid. 2015; 25 (PubMed PMID: 25900731; PMCID: PMC4854274): 716-759https://doi.org/10.1089/thy.2014.0460
- Bilateral papillary thyroid cancer in children: Risk factors and frequency of postoperative diagnosis.J Pediatr Surg. 2020; 55 (PubMed PMID: 32171533): 1117-1122https://doi.org/10.1016/j.jpedsurg.2020.02.040
- NTRK- and RET-fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.J Clin Invest. 2021; (PubMed PMID: 34237031)https://doi.org/10.1172/JCI144847
- Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib.Biologics. 2014; 8 (PubMed PMID: 24748771; PMCID: PMC3990290): 129-139https://doi.org/10.2147/BTT.S39381
- Multikinase inhibitors in thyroid cancer: timing of targeted therapy.Nat Rev Endocrinol. 2021; 17 (PubMed PMID: 33603220): 225-234https://doi.org/10.1038/s41574-020-00465-y
- Entrectinib: first global approval.Drugs. 2019; 79 (PubMed PMID: 31372957): 1477-1483https://doi.org/10.1007/s40265-019-01177-y
- Larotrectinib: first global approval.Drugs. 2019; 79 (PubMed PMID: 30635837): 201-206https://doi.org/10.1007/s40265-018-1044-x
- NTRK fusion-positive cancers and TRK inhibitor therapy.Nat Rev Clin Oncol. 2018; 15 (PubMed PMID: 30333516; PMCID: PMC6419506): 731-747https://doi.org/10.1038/s41571-018-0113-0
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.Lancet Oncol. 2018; 19 (PubMed PMID: 29606586; PMCID: PMC5949072): 705-714https://doi.org/10.1016/S1470-2045(18)30119-0
- Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children.N Engl J Med. 2018; 378 (PubMed PMID: 29466156; PMCID: PMC5857389): 731-739https://doi.org/10.1056/NEJMoa1714448
- Trial I. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.Lancet Oncol. 2020; 21 (PubMed PMID: 31838007; PMCID: PMC7461630): 271-282https://doi.org/10.1016/S1470-2045(19)30691-6
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.Lancet Oncol. 2020; 21 (PubMed PMID: 32105622; PMCID: PMC7497841): 531-540https://doi.org/10.1016/S1470-2045(19)30856-3
- Agnostic-histology approval of new drugs in oncology: are we already there?.Clin Cancer Res. 2019; 25 (PubMed PMID: 30670489): 3210-3219https://doi.org/10.1158/1078-0432.CCR-18-3694
- From tissue-agnostic to N-of-one therapies: (R)evolution of the precision paradigm.Trends Cancer. 2021; 7 (PubMed PMID: 33008795): 15-28https://doi.org/10.1016/j.trecan.2020.08.009
- Tissue-agnostic anti-cancer drugs.Pharmaceuticals (Basel). 2021; 14 (PubMed PMID: 34209967; PMCID: PMC8308490)https://doi.org/10.3390/ph14070632
- Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges.J Exp Clin Cancer Res. 2021; 40 (PubMed PMID: 34090508; PMCID: PMC8178911): 185https://doi.org/10.1186/s13046-021-01981-z
- Histology-based molecular profiling improves mutation detection for advanced thyroid cancer.Genes Chromosomes Cancer. 2021; 60 (PubMed PMID: 33749950): 531-545https://doi.org/10.1002/gcc.22949
- Locally recurrent secretory carcinoma of the breast with NTRK3 gene fusion.Oncologist. 2021; (PubMed PMID: 34176200)https://doi.org/10.1002/onco.13880
- Comprehensive tumor molecular profile analysis in clinical practice.BMC Med Genomics. 2021; 14 (PubMed PMID: 33853586; PMCID: PMC8045191): 105https://doi.org/10.1186/s12920-021-00952-9
- Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer.Mol Med. 2021; 27 (PubMed PMID: 34217228; PMCID: PMC8254966): 68https://doi.org/10.1186/s10020-021-00331-1
- Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer.Oral Oncol. 2021; 119 (PubMed PMID: 34098386)105369https://doi.org/10.1016/j.oraloncology.2021.105369
- The therapeutic implications of the genomic analysis of malignant pleural mesothelioma.Nat Commun. 2021; 12 (PubMed PMID: 33753750; PMCID: PMC7985484): 1819https://doi.org/10.1038/s41467-021-22142-y
- Beyond conventional: the new horizon of targeted therapy for the treatment of advanced non small cell lung cancer.Front Oncol. 2021; 11 (PubMed PMID: 34094913; PMCID: PMC8176852)632256https://doi.org/10.3389/fonc.2021.632256
- Mosaicism for receptor tyrosine kinase activation in a glioblastoma involving both PDGFRA amplification and NTRK2 fusion.Oncologist. 2021; (PubMed PMID: 34041811)https://doi.org/10.1002/onco.13835
- Dramatic response of STRN-NTRK-fused malignant glioneuronal tumor to larotrectinib in adult.Neuro Oncol. 2021; 23 (PubMed PMID: 34057471; PMCID: PMC8248836): 1200-1202https://doi.org/10.1093/neuonc/noab080
- Diagnostic challenges and successful organ-preserving therapy in a case of secretory carcinoma of minor salivary glands.Cancer Rep (Hoboken). 2021; (PubMed PMID: 34231337): e1491https://doi.org/10.1002/cnr2.1491
- Resistance to TRK inhibition mediated by convergent MAPK pathway activation.Nat Med. 2019; 25 (PubMed PMID: 31406350; PMCID: PMC6736691): 1422-1427https://doi.org/10.1038/s41591-019-0542-z
- Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers.Acta Pharm Sin B. 2021; 11 (PubMed PMID: 33643817; PMCID: PMC7893124): 355-372https://doi.org/10.1016/j.apsb.2020.05.004
- Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer.Cancer Discov. 2016; 6 (PubMed PMID: 26546295): 36-44https://doi.org/10.1158/2159-8290.CD-15-0940
- Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent- front mutations.Cancer Discov. 2018; 8 (PubMed PMID: 30093503): 1227-1236https://doi.org/10.1158/2159-8290.CD-18-0484
- Phase I first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors.Clin Cancer Res. 2020; 26 (PubMed PMID: 32591465): 4785-4794https://doi.org/10.1158/1078-0432.CCR-20-1630
- Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.Lancet Diabetes Endocrinol. 2014; 2 (PubMed PMID: 24898835): 830-842https://doi.org/10.1016/S2213-8587(14)70051-8
- Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.J Clin Invest. 2011; 121 (Epub 2011/11/23PubMed PMID: 22105174; PMCID: 3225989): 4700-4711https://doi.org/10.1172/JCI46382
- Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.N Engl J Med. 2013; 368 (PubMed PMID: 23406027): 623-632https://doi.org/10.1056/NEJMoa1209288
- Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.J Clin Investig. 2016; 126: 4119-4124https://doi.org/10.1172/jci89067
- Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer.N Engl J Med. 2020; 383 (PubMed PMID: 33085869): 1686-1687https://doi.org/10.1056/NEJMc2023094
- Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.Oncotarget. 2018; 9 (PubMed PMID: 29568395; PMCID: PMC5862616): 13796-13806https://doi.org/10.18632/oncotarget.24488
- NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.Commun Biol. 2020; 3 (PubMed PMID: 33328556; PMCID: PMC7745027): 776https://doi.org/10.1038/s42003-020-01508-w
- An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101.Cancer Discov. 2015; 5 (PubMed PMID: 26216294; PMCID: PMC4635026): 1049-1057https://doi.org/10.1158/2159-8290.CD-15-0443
- The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium.Oncogene. 2000; 19 (PubMed PMID: 11126359): 5729-5735https://doi.org/10.1038/sj.onc.1203922
- Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice.Endocr Relat Cancer. 2009; 16 (PubMed PMID: 19261681): 483-490https://doi.org/10.1677/ERC-08-0272
- Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer.Nat Med. 2020; 26 (PubMed PMID: 33020650): 1742-1753https://doi.org/10.1038/s41591-020-1072-4
- Modeling the developmental origins of pediatric cancer to improve patient outcomes.Dis Model Mech. 2021; 14 (PubMed PMID: 33619212; PMCID: PMC7927656)https://doi.org/10.1242/dmm.048930
- Combined BRAF(V600E) and MEK blockade for BRAF(V600E)-mutant gliomas.J Neurooncol. 2017; 131 (PubMed PMID: 27848137; PMCID: PMC5560871): 495-505https://doi.org/10.1007/s11060-016-2333-4
- Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.Cancer Res. 2010; 70 (PubMed PMID: 20068183; PMCID: PMC2851233): 512-519https://doi.org/10.1158/0008-5472.CAN-09-1851
- Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy.Proc Natl Acad Sci U S A. 2012; 109 (PubMed PMID: 22586120; PMCID: PMC3365162): 8710-8715https://doi.org/10.1073/pnas.1117255109
- The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance.Oncotarget. 2016; 7 (PubMed PMID: 27304190; PMCID: PMC5216757): 45745-45756https://doi.org/10.18632/oncotarget.9935
- Testing susceptibility of patient-derived organoid cultures to therapies: pharmacotyping.Methods Mol Biol. 2018; 1787 (PubMed PMID: 29736724): 253-261https://doi.org/10.1007/978-1-4939-7847-2_19
- Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model.Cancer Cell. 2003; 4 (PubMed PMID: 14522252): 181-189https://doi.org/10.1016/s1535-6108(03)00220-4
- Integrated genomic characterization of papillary thyroid carcinoma.Cell. 2014; 159: 676-690https://doi.org/10.1016/j.cell.2014.09.050
Article Info
Publication History
Published online: March 05, 2022
Accepted:
February 27,
2022
Received in revised form:
January 31,
2022
Received:
August 27,
2021
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
